Ankasa Regenerative Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 1K
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion
Phase 1
- Conditions
- Degenerative Spondylolisthesis
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Ankasa Regenerative Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04378543
- Locations
- 🇺🇸
Keck School of Medicine, University of Southern California, Los Angeles, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Wexner Medical Center, The Ohio State University, Columbus, Ohio, United States
News
No news found